Sec Form 4 Filing - DCVC Bio, L.P. @ AbCellera Biologics Inc. - 2021-06-18

Every director, officer or owner of more than ten percent of a class of equity securities registered under Section 12 of the '34 Act must file with the U.S. Securities and Exchange Commission (SEC) a statement of ownership regarding such security.

Form 4: Statement of changes in beneficial ownership, filed before the end of the 2nd business day following the day on which a transaction resulting in a change in beneficial ownership.

"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
The following is an SEC EDGAR document rendered as filed.
Here is the list of insider trading transaction codes.

FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: November 30, 2011
Estimated average burden hours per response... 0.5
1. Name and Address of Reporting Person *
DCVC Bio, L.P.
2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director X __ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
270 UNIVERSITY AVENUE
3. Date of Earliest Transaction (MM/DD/YY)
06/18/2021
(Street)
PALO ALTO, CA94301
4. If Amendment, Date Original Filed (MM/DD/YY)
6. Individual or Joint/Group Filing (Check Applicable Line)
_____ Form filed by One Reporting Person
__ X __ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Shares 06/18/2021 J( 1 ) 5,000,000 D $ 0 ( 1 ) 24,105,761 I See Footnote ( 2 ) ( 3 )
Common Shares 06/18/2021 J( 1 ) 73,892 A $ 0 ( 1 ) 73,892 I See Footnote ( 4 ) ( 5 )
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(MM/DD/YY)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Reporting Owners
Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
DCVC Bio, L.P.
270 UNIVERSITY AVENUE
PALO ALTO, CA94301
X
DCVC Bio GP, LLC
270 UNIVERSITY AVENUE
PALO ALTO, CA94301
X
JNK Capital Management, LLC
270 UNIVERSITY AVENUE
PALO ALTO, CA94301
X
ZNM Capital Management, LLC
270 UNIVERSITY AVENUE
PALO ALTO, CA94301
X
Bogue Zachary
270 UNIVERSITY AVENUE
PALO ALTO, CA94301
X
Ocko Matthew
270 UNIVERSITY AVENUE
PALO ALTO, CA94301
X
Stead Kiersten
270 UNIVERSITY AVENUE
PALO ALTO, CA94301
X
Signatures
DCVC Bio, L.P. By: DCVC Bio GP, LLC Its: General Partner By: ZNM Capital Management, LLC Its: Managing Member By: /s/ Matthew Ocko Matthew Ocko, Managing Member 06/21/2021
** Signature of Reporting Person Date
DCVC Bio GP, LLC, By: ZNM Capital Management, LLC Its: Managing Member By: /s/ Matthew Ocko Matthew Ocko, Managing Member 06/21/2021
** Signature of Reporting Person Date
JNK Capital Management, LLC, By: /s/ Kiersten Stead Kiersten Stead, Managing Member 06/21/2021
** Signature of Reporting Person Date
ZNM Capital Management, LLC By: /s/ Matthew Ocko Matthew Ocko, Managing Member 06/21/2021
** Signature of Reporting Person Date
Zachary Bogue /s/ Zachary Bogue 06/21/2021
** Signature of Reporting Person Date
Matthew Ocko /s/ Matthew Ocko 06/21/2021
** Signature of Reporting Person Date
Kiersten Stead /s/ Kiersten Stead 06/21/2021
** Signature of Reporting Person Date
Explanation of Responses:
( 1 )On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended.
( 2 )These securities are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio.
( 3 )(Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any.
( 4 )These securities are held by DCVC Bio GP. JNK and ZNM are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio GP. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio GP.
( 5 )(Continued from Footnote 4) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any.

Remarks:
This is one of two Form 4s filed on the date hereof in respect of these securities. The Reporting Person for the other Form 4 is John Hamer.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.